RU2022105827A - Слитые конструкции антител для вовлечения nk-клеток - Google Patents

Слитые конструкции антител для вовлечения nk-клеток Download PDF

Info

Publication number
RU2022105827A
RU2022105827A RU2022105827A RU2022105827A RU2022105827A RU 2022105827 A RU2022105827 A RU 2022105827A RU 2022105827 A RU2022105827 A RU 2022105827A RU 2022105827 A RU2022105827 A RU 2022105827A RU 2022105827 A RU2022105827 A RU 2022105827A
Authority
RU
Russia
Prior art keywords
amino acid
acid sequence
binding protein
seq
multispecific antigen
Prior art date
Application number
RU2022105827A
Other languages
English (en)
Russian (ru)
Inventor
Майкл ТЕСАР
Кристина Эллвангер
Ивика ФУСЕК
Уве РАУШ
Торстен Росс
Йоаким КОХ
Эрик РАДЖКОВИЧ
Мартин Тредер
Original Assignee
Аффимед Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аффимед Гмбх filed Critical Аффимед Гмбх
Publication of RU2022105827A publication Critical patent/RU2022105827A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2022105827A 2018-04-13 2019-04-12 Слитые конструкции антител для вовлечения nk-клеток RU2022105827A (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP18167384.9 2018-04-13
EP18167385.6 2018-04-13
EP18167384 2018-04-13
EP18167385 2018-04-13
EP18190662 2018-08-24
EP18190661.1 2018-08-24
EP18190661 2018-08-24
EP18190662.9 2018-08-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2020134591A Division RU2774711C2 (ru) 2018-04-13 2019-04-12 Слитые конструкции антител для вовлечения nk-клеток

Publications (1)

Publication Number Publication Date
RU2022105827A true RU2022105827A (ru) 2022-04-05

Family

ID=66625219

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2022105827A RU2022105827A (ru) 2018-04-13 2019-04-12 Слитые конструкции антител для вовлечения nk-клеток

Country Status (21)

Country Link
US (3) US11001633B2 (cg-RX-API-DMAC7.html)
EP (1) EP3774914A2 (cg-RX-API-DMAC7.html)
JP (2) JP2021521275A (cg-RX-API-DMAC7.html)
KR (1) KR20200143436A (cg-RX-API-DMAC7.html)
CN (3) CN113817066A (cg-RX-API-DMAC7.html)
AU (2) AU2019252970A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020020828A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095373A1 (cg-RX-API-DMAC7.html)
CL (2) CL2020002625A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020014167A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200549A (cg-RX-API-DMAC7.html)
IL (1) IL277925A (cg-RX-API-DMAC7.html)
MA (1) MA52227A (cg-RX-API-DMAC7.html)
MX (1) MX2020010728A (cg-RX-API-DMAC7.html)
PE (1) PE20201346A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551664B1 (cg-RX-API-DMAC7.html)
RU (1) RU2022105827A (cg-RX-API-DMAC7.html)
SG (1) SG11202010064QA (cg-RX-API-DMAC7.html)
TW (1) TW202012441A (cg-RX-API-DMAC7.html)
WO (1) WO2019198051A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006325B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220396635A1 (en) * 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
US12698331B2 (en) 2019-12-10 2026-08-04 Institut Pasteur Antibody blocking human FcγRIIIA and FcγRIIIB
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
EP4545569A3 (en) * 2020-06-30 2025-10-08 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
EP4225792A1 (en) 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
TW202233248A (zh) * 2020-11-08 2022-09-01 美商西健公司 組合療法
MX2023006573A (es) * 2020-12-03 2023-06-19 Amgen Inc Constructos de inmunoglobulina con multiples dominios de union.
US20240101677A1 (en) * 2021-01-27 2024-03-28 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof
JP2024516230A (ja) 2021-04-30 2024-04-12 ジェネンテック, インコーポレイテッド がんのための治療及び診断方法並びに組成物
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
US20250206823A1 (en) * 2021-07-30 2025-06-26 Qure Biotechnology (Shanghai) Co., Ltd. Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
CA3233085A1 (en) * 2021-09-24 2023-03-30 Synergy Imt, Inc. Composition of recombinant antigen binding molecules and method of making and using thereof
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
TW202334221A (zh) 2021-11-03 2023-09-01 德商安富美德有限公司 雙特異性cd16a結合劑
CN116284385A (zh) * 2021-12-07 2023-06-23 信达细胞制药(苏州)有限公司 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
JP2025528087A (ja) * 2022-08-05 2025-08-26 チマゲン・バイオサイエンシズ,リミテッド 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体
AU2023343472A1 (en) * 2022-09-14 2025-03-20 Otsuka Pharmaceutical Co., Ltd. Pd-1 agonist antibodies
JP2026504499A (ja) * 2023-02-06 2026-02-05 レプ バイオファーマ カンパニー, リミテッド 抗cd16a抗体およびその使用
KR20240136856A (ko) * 2023-03-06 2024-09-19 주식회사 드노보 바이오테라퓨틱스 신규한 항-cd16 항체 및 이의 용도
WO2025257588A1 (en) * 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
WO2026087751A1 (en) 2024-10-24 2026-04-30 Affimed Gmbh Combination of immune cell engager and nk cell products
WO2026101948A1 (en) * 2024-11-05 2026-05-15 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP4751777A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a vegfr-2 inhibitor
EP4751731A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane
EP4751734A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Bispecific antibody construct dosage regimen for treating nsclc
CN121362261A (zh) * 2025-10-30 2026-01-20 北京再青生物科技有限公司 一种靶向T细胞及Her2的双特异性抗体并串联IL-15及其受体的融合蛋白及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
LT2361936T (lt) * 2010-02-25 2016-09-12 Affimed Gmbh Antigeną rišanti molekulė ir jos panaudojimas
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
WO2013138643A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Soluble engineered monomeric fc
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
EP2970485A1 (en) * 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3091031A1 (en) * 2015-05-04 2016-11-09 Affimed GmbH Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
CA2983706C (en) * 2015-05-04 2024-01-02 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
AU2016284871B2 (en) * 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
WO2018158349A1 (en) * 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement

Also Published As

Publication number Publication date
US20200109202A1 (en) 2020-04-09
WO2019198051A3 (en) 2019-11-14
CL2023001085A1 (es) 2023-10-06
JP2025081307A (ja) 2025-05-27
PH12020551664A1 (en) 2021-12-13
US20240294647A1 (en) 2024-09-05
CN112119097B (zh) 2021-10-15
CR20200549A (es) 2021-03-18
CN113880952A (zh) 2022-01-04
CO2020014167A2 (es) 2021-04-08
MX2020010728A (es) 2020-11-06
EP3774914A2 (en) 2021-02-17
SG11202010064QA (en) 2020-11-27
IL277925A (en) 2020-11-30
TW202012441A (zh) 2020-04-01
US11001633B2 (en) 2021-05-11
US20210253698A1 (en) 2021-08-19
AU2019252970A1 (en) 2020-11-26
JP2021521275A (ja) 2021-08-26
PH12020551664B1 (en) 2023-05-19
MA52227A (fr) 2021-04-21
AU2026200541A1 (en) 2026-02-19
CN113817066A (zh) 2021-12-21
CA3095373A1 (en) 2019-10-17
PE20201346A1 (es) 2020-11-25
ZA202006325B (en) 2025-12-17
CN112119097A (zh) 2020-12-22
WO2019198051A2 (en) 2019-10-17
CL2020002625A1 (es) 2021-02-19
KR20200143436A (ko) 2020-12-23
BR112020020828A2 (pt) 2021-01-19

Similar Documents

Publication Publication Date Title
JP2021521275A5 (cg-RX-API-DMAC7.html)
KR102607909B1 (ko) 항-cd28 조성물
JP7809680B2 (ja) 癌処置のための多重特異性結合タンパク質
EP3694882B1 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
US11932675B2 (en) PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties
US10882922B2 (en) Trispecific and/or trivalent binding proteins
JP2022504550A (ja) Pd-1標的化il-15/il-15rアルファfc融合タンパク質およびその組み合わせ療法での使用
JP2022502052A5 (cg-RX-API-DMAC7.html)
JP2020115876A (ja) Pd−l1に対するヒト抗体
JP2018525382A5 (cg-RX-API-DMAC7.html)
EP3953388A1 (en) Trispecific binding proteins, methods, and uses thereof
JP2021513961A (ja) 変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用
AU2020379757A1 (en) Methods of treatment with antibodies against BCMA and CD3
WO2021092060A1 (en) Methods of treatment
CN110267990A (zh) 结合共刺激性和检查点受体的双特异性免疫调节抗体
TW202220691A (zh) 用於使用PD—1xCTLA—4雙特異性分子的方法
JP2025069255A (ja) 抗pd-1抗体及びその用途
WO2024077044A1 (en) Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
US20250161355A1 (en) Proteins for modulating cell therapy products and methods of use thereof
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
CA3212336A1 (en) Methods for treating multiple myeloma
HK40100622A (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
EA049502B1 (ru) Мультиспецифические связывающие белки для лечения рака
RU2020134591A (ru) Слитые конструкции антител для вовлечения nk-клеток
RU2019118800A (ru) Антигенсвязывающие белки против gitr и способы их прменения